Söderholm J, Ahlén G, Kaul A, Frelin L, Alheim M, Barnfield C, Liljeström P, Weiland O, Milich D R, Bartenschlager R, Sällberg M
Division of Clinical Virology, Karolinska Institutet at Karolinska University Hospital, S-141 86 Stockholm, Sweden.
Gut. 2006 Feb;55(2):266-74. doi: 10.1136/gut.2005.072231. Epub 2005 Aug 16.
The hepatitis C virus (HCV) mutates within human leucocyte antigen (HLA) class I restricted immunodominant epitopes of the non-structural (NS) 3/4A protease to escape cytotoxic T lymphocyte (CTL) recognition and promote viral persistence. However, variability is not unlimited, and sometimes almost absent, and factors that restrict viral variability have not been defined experimentally.
We wished to explore whether the variability of the immunodominant CTL epitope at residues 1073-1081 of the NS3 protease was limited by viral fitness.
Venous blood was obtained from six patients (four HLA-A2+) with chronic HCV infection and from one HLA-A2+ patient with acute HCV infection.
NS3/4A genes were amplified from serum, cloned in a eukaryotic expression plasmid, sequenced, and expressed. CTL recognition of naturally occurring and artificially introduced escape mutations in HLA-A2-restricted NS3 epitopes were determined using CTLs from human blood and genetically immunised HLA-A2-transgenic mice. HCV replicons were used to test the effect of escape mutations on HCV protease activity and RNA replication.
Sequence analysis of NS3/4A confirmed low genetic variability. The major viral species had functional proteases with 1073-1081 epitopes that were generally recognised by cross reactive human and murine HLA-A2 restricted CTLs. Introduction of mutations at five positions of the 1073-1081 epitope prevented CTL recognition but three of these reduced protease activity and RNA replication.
Viral fitness can indeed limit the variability of HCV within immunological epitopes. This helps to explain why certain immunological escape variants never appear as a major viral species in infected humans.
丙型肝炎病毒(HCV)在人类白细胞抗原(HLA)I类限制性免疫显性表位的非结构(NS)3/4A蛋白酶内发生突变,以逃避细胞毒性T淋巴细胞(CTL)的识别并促进病毒持续存在。然而,变异性并非无限制,有时几乎不存在,且限制病毒变异性的因素尚未通过实验确定。
我们希望探讨NS3蛋白酶1073 - 1081位氨基酸处免疫显性CTL表位的变异性是否受病毒适应性限制。
从6例慢性HCV感染患者(4例HLA - A2阳性)和1例急性HCV感染的HLA - A2阳性患者采集静脉血。
从血清中扩增NS3/4A基因,克隆到真核表达质粒中,测序并表达。使用来自人血的CTL和基因免疫的HLA - A2转基因小鼠确定HLA - A2限制性NS3表位中天然存在和人工引入的逃逸突变的CTL识别情况。使用HCV复制子测试逃逸突变对HCV蛋白酶活性和RNA复制的影响。
NS3/4A的序列分析证实遗传变异性较低。主要病毒株具有功能性蛋白酶,其1073 - 1081表位通常被交叉反应的人和鼠HLA - A2限制性CTL识别。在1073 - 1081表位的5个位置引入突变可阻止CTL识别,但其中3个突变降低了蛋白酶活性和RNA复制。
病毒适应性确实可以限制HCV在免疫表位内的变异性。这有助于解释为什么某些免疫逃逸变体在受感染人类中从未作为主要病毒株出现。